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Tumour suppressor p21WAF1/CIP1 is the main downstream effector
gene mediating p53-induced cell cycle arrest, up-regulated by
normal wild-type p53 (El-Deiry et al, 1993). In addition to direct
transcriptional induction by the tumour suppressor p53, various
other signals can induce p21 expression in the absence of wild-
type p53 (Michieli et al, 1994; Zeng and El-Deiry, 1996). Harper
et al (1993) showed that the ability of the p21 gene product to
arrest the cell cycle is based on its virtue to bind and inhibit active
cyclin/CDK complexes needed in DNA replication and cell cycle
progression. p21 can also inhibit DNA replication by directly
binding to the proliferating cell nuclear antigen (PCNA) molecule,
thus inhibiting the ability of DNA polymerase d to extend new
DNA chains but still allowing the DNA repair function to continue
(Flores-Rozas et al, 1994; Waga et al, 1994; Podust et al, 1995).
In human melanoma cell lines, induction of p21 is independent
of wild-type p53 expression (Jiang et al, 1995; Vidal et al, 1995),
and elevated expression of p21 is associated with melanoma
differentiation, growth arrest and metastatic suppression (Jiang et
al, 1995). However, the knowledge of p21 expression in clinical
materials of cutaneous malignant melanoma is rather limited.
Maelandsmo et al (1996) revealed a significant correlation
between elevated p21 expression and increasing tumour thickness
in superficially spreading melanoma, but no correlation
between p21 and survival was found. Elsewhere, a significant
overexpression of p21 has been demonstrated in primary and
metastatic melanomas (Trotter et al, 1997).
As far as the authors are aware, no previous study has compared
the relationships between p21, p53 and PCNA expression in
primary stage I cutaneous melanoma. In the present study, we used
immunohistochemistry to analyse the above-mentioned relation-
ships in a cohort of 369 patients with long-term follow-up data. In
addition, our aim was to analyse whether p21 protein levels are
related to clinical data, histological parameters (Clark and Breslow
levels) and prognosis.
MATERIALS AND METHODS
Patients
The retrospective study consists of a consecutive series of 369 clin-
ical stage I cutaneous malignant melanoma patients with complete
clinical and histopathological data available, who were diagnosed
and treated in the district of Kuopio University Hospital, Finland,
between 1974 and 1989. The clinical staging of all tumours was
carried out according to UICC (UICC, 1987). Because of insuffi-
cient tumour material, pigment or technical artefacts, there were
267 valid immunostainings for p21, 284 for p53 and 219 for PCNA
respectively. Patient records were reviewed and the pertinent clin-
ical and histopathological data of the patients are shown in Table 1.
The mean follow-up time of all 369 patients was 6.4 years (range
0.2–18 years). When the analysis was restricted to patients with
p21, p53 or PCNA data, the mean follow-up times were 6.3 years
(range 0.5–18 years), 6.3 years (range 0.5–18 years) or 7.2 years
(range 0.5–18 years) respectively. The cause of death was obtained
from the patient records and from the files of the Finnish Cancer
Registry and General Statistical Office in Finland.
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The formalin-fixed, paraffin-embedded samples were sectioned at
5 mm and stained with haematoxylin and eosin (HE). The histolog-
ical diagnosis was confirmed by reviewing 1–4 original sections of
the primary tumour. Tumour thickness according to Breslow
(1970) and level of invasion according to Clark et al (1969) were
re-examined from the most representative slide by the same
pathologist (VMK), unaware of the clinical data. In addition, the
most representative block was selected to be cut into new 5-mm-
thick sections for immunohistochemical studies.
Immunohistochemistry
p21 and p53 stainings
Sections were deparaffinized, rehydrated, washed twice for 5 min
with distilled water and boiled in a microwave oven in citrate
buffer (pH 6.0) for 5 ´ 5 min for antigen retrieval. Endogenous
peroxidase activity was blocked by 5% hydrogen peroxide for
5 min, followed by washings for 2 ´ 3 min with distilled water and
2 ´ 5 min with phosphate-buffered saline (PBS) (pH 7.2). After
eliminating non-specific staining with normal horse serum, the
tissue sections were incubated overnight at 4°C with a p21-
specific mouse monoclonal antibody (NCL-WAF-1, Novocastra
Laboratories, UK) at a working dilution of 1:10. Samples were
washed twice for 5 min with PBS and incubated for 30 min with
biotinylated secondary antibody (Vectastain ABC Elite Kit, Vector
Laboratories, CA, USA) in PBS. After two washings for 5 min in
PBS, the sections were incubated for 40 min in preformed
avidin–biotinylated–peroxidase complex solution. Samples were
washed for 2 ´ 5 min with PBS, developed with diaminobenzidine
tetrahydrochloride (DAB) substrate (Sigma, UK) for 5 min,
slightly counterstained with Mayer’s haematoxylin, dehydrated,
cleared and mounted with DePex (BDH, Poole, UK).
The p53 protein was demonstrated by means of the same
staining protocol. We used a monoclonal D07 (Dako, Denmark)
antibody, known to be specific for both mutant and wild-type
forms of the p53 protein (Vojtesek et al, 1992), at a working dilu-
tion of 1:1000. For antigen retrieval, the samples were boiled in a
microwave oven twice for 5 min in citrate buffer (pH 6.0). In each
batch, known p53- and p21-positive melanoma tumour samples
were used as positive controls, and the same biopsy processed
without the primary antibody was used as a negative control.
PCNA staining
The staining protocol used in PCNA immunostaining has been
described previously (Aaltomaa et al, 1993). In brief, 5-mm paraffin
sections were deparaffinized and rehydrated. After blocking of
endogenous peroxidase with 5% hydrogen peroxide and inhibition of
non-specific staining with normal goat serum, the sections were incu-
bated overnight with the PC10 (Dako) anti-PCNA monoclonal anti-
body diluted at 1:350 in PBS (pH 7.2) at 4°C. No antigen retrieval
was used. Sections were washed twice for 5 min with PBS and incu-
bated for 30 min with horse antimouse biotinylated secondary anti-
body (Vectastain ABC Elite Kit, Vector Laboratories, CA, USA)
diluted at 1:200 in PBS (pH 7.2). After washing twice for 5 min in
PBS, sections were incubated for 40 min in preformed avidin–
biotin–peroxidase complex solution. The colour reaction was
demonstrated with a chromogen (DAB) as described for p21. Normal
human tonsil was used as a positive control, and the same biopsy
processed without the primary antibody served as a negative control.
Scoring and quantitation of the immunoreactivities
All slides were evaluated with a dual-head microscope (field
diameter 490 mm) by two observers (JMK and VMK for p21 and
p53, MR and VMK for PCNA), who were unaware of the clinical
outcome of the patients. For p21 and p53, the positivity was
assessed as the percentage of positively stained tumour cell nuclei
in the entire tumour area. The p21 positivity was scored as
follows: 0 (< 1% positive), 1 (1–10% positive), 2 (10–20% posi-
tive) or 3 (> 20% positive). A semiquantitative grading was used
for p53 staining, taking into account both staining intensity and
proportion of positive tumour cells. Intensity was recorded from 0
(no cells positive) to 3 (strong staining). A staining index was then
calculated by multiplying the fraction of stained nuclei (%) by the
staining intensity (0–3). For statistical purposes, the tumours were
divided according to this index into four groups: group 0 (0, n =
91), group 1 (≤ 1, n = 59), group 2 (1–10, n = 83), and group 3
(> 10, n = 51).
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Table 1 Clinical and histopathological data of 369 patients with stage I
cutaneous malignant melanoma
Gender
Male 178
Female 191
Age (years)
Mean (s.d.) 55.5 (15.2)
Range 19.0–89.7
Anatomic site
Head and neck 64
Trunk and perineum 173
Upper limbs 58
Lower limbs 74
Bleeding of the primary tumour
Yes 98
No 152
Data not available 119
Growth of the primary tumour
Yes 200
No 38
Data not available 131
Cause of death
Malignant melanoma 66
Other 46
Alive 257
Recurrent disease
Yes 106
No 263
Clark’s level
I2 1
II 68
III 106
IV 145
V2 9
Tumour thickness
≤0.75 mm 82
0.76–1.50 mm 88
1.51–4.0 mm 120
>4.0 mm 50
Not possible to analyse 29
TNM category
pT1 or T2, N0, M0 174
pT3, N0, M0 139
pT4, N0, M0 56The PCNA positivity was scored as the fraction (%) of posi-
tively stained tumour cell nuclei evaluated in ten microscopic
fields (diameter 490 mm, objective magnification 40´, corre-
sponding to 0.194 mm2 of neoplastic epithelium) from the area of
the highest immunopositivity (PCNAtot) (Aaltomaa et al, 1993).
The immunopositivity was further divided into two groups: low
PCNAtot (≤ 35% of cells positive, n = 114) and high PCNAtot
(> 35% of cells positive, n = 105).
Statistical analyses
The SPSS-Win 7.5 program package was used in a PC computer for
basic statistical calculations. First, the relationships (Spearman rank
correlations) between p21, p53 and PCNA expression levels as well
as tumour thickness were analysed using each parameter as a contin-
uous variable. For all further statistical analyses, immunohisto-
chemically determined parameters were categorized as previously
described. The interrelationships between these immunohistochem-
ical variables and their association with clinicopathological parame-
ters were examined by contingency tables, which were further
analysed by c2 tests. Univariate survival analyses were based on the
Kaplan–Meier method (log-rank analysis) (Kaplan and Meier, 1958).
To assess the prognostic significance of dichotomic immunohisto-
chemical variables (p21 expression, p53 index and PCNAtot) within
each Breslow thickness subgroup, we made both univariate
Kaplan–Meier and multivariate subset analyses within each Breslow
category, as well as in tumours with Breslow thickness < 1.5 mm and
> 1.5 mm. Multivariate survival analyses were carried out with the
SPSS-Cox (Cox 1972) program package using the log likelihood
ratio significance test in both forward and backward stepwise
manner. Overall survival (OS) analysis included as an event only the
deaths due to malignant melanoma. Deaths due to post-operative
complications within 30 days were excluded. Recurrence-free
survival (RFS) was defined as the time elapsed between the primary
treatment and the recurrence of melanoma. For all statistical tests, a
critical significance level of 5% was chosen. In Cox’s multivariate
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Table 2 Expression of p21, p53 and PCNA in stage I cutaneous malignant
melanoma
Immunostaining n %
p21
0 (<1%) 44 17
1 (1–10%) 103 39
2 (10–20%) 58 22
3 (>20%) 62 23
Total 267 100
p53 index
0 (0) 91 32
1 (≤1) 59 21
2 (1–10) 83 29
3 (>10) 51 18
Total 284 100
PCNAtot
Low (≤35%) 114 52
High (>35%) 105 48
Total 219 100
PCNAtot, PCNA expression in ten consecutive high-power fields; p53 index,
(% of p53-positive tumour cells) ´ (staining intensity of p53).
Table 3 Correlation between p21, p53 and PCNA expression and tumour
thickness in stage I cutaneous malignant melanoma
Variables n Spearman’s Two-tailed
correlation significance
coefficient
p21 vs. p53 index 255 0.177 0.005
p21 vs. PCNAtot 181 0.368 <0.00005
p21 vs. tumour thickness 251 –0.164 0.009
p53 index vs. PCNAtot 194 0.296 <0.00005
p53 index vs. tumour thickness 265 0.020 0.742
PCNAtot vs. tumour thickness 207 –0.046 0.511
PCNAtot, PCNA expression in ten consecutive high power fields; p53 index,
(% of p53-positive tumour cells) ´ (staining intensity of p53).
A
B
C
Figure 1 Immunohistochemical stainings of cutaneous malignant
melanoma. (A) Cutaneous malignant melanoma showing strong p21
immunopositivity. (B) An adjacent section showing only few p53-positive
tumour cell nuclei. (C) PCNA immunostaining of the same specimen showing
strong PCNA signal. Bar, 60 mmanalysis, a removal limit of P < 0.10 was used as an additional
inclusion criteria.
RESULTS
p21 expression
Of the 267 valid immunostainings for p21 analysis, 84% of the
tumours showed at least 1% of their nuclei to express p21 protein.
The distribution of p21 expression into different categories is
shown in Table 2. The positive staining was remarkably confined
to the tumour cell nuclei (Figure 1A). The detected p21 expression
level was significantly related to p53 staining index and to prolif-
eration assessed by PCNAtot (Tables 3 and 4), but p21 was also
inversely related to p53 as shown in Table 4. In addition, reduced
level of p21 expression was significantly associated with high
tumour thickness (c2 = 5.76, P = 0.016, n = 267; see also Table 3),
recurrent disease (c2 = 4.26, P = 0.039, n = 267), high TNM cate-
gory (c2 = 4.92, P = 0.027, n = 267), and older (³ 55 years) age at
the time of diagnosis (c2 = 4.16, P = 0.041, n = 267) (other data not
shown). No significant associations were observed between the
p21 expression level and gender or bleeding (data not shown).
p53 expression
There were 284 immunostainings available for p53 analysis, of
which 68% showed detectable levels (> 0%) of protein accumula-
tion. Only about 20% of the tumours showed p53 immunopositivity
in more than 5% of the tumour cell nuclei, and the p53 staining
index was over 10 in 18% of the cases (Table 2). The p53 staining
was confined mostly to the tumour cell nuclei (Figure 1B), but in
14% of the cases cytoplasmic staining was also detectable.
There was a strong statistically significant association between
high p53 staining index and high proliferation (PCNAtot) (Tables
3 and 4). Of the p53 staining index-negative tumours, 65% showed
low PCNAtot (≤ 35%) expression levels, whereas only 35% of the
tumours with high p53 staining index (> 10) showed low PCNAtot
levels (c2 = 9.225, P = 0.002; Table 4). The p53 staining index and
tumour thickness were not statistically interrelated (Table 3),
whereas a significant association was observed between the high
p53 staining index and recurrent disease (c2 = 5.853, P = 0.016;
other data not shown).
PCNA expression
Detectable levels (> 0%) of PCNA positivity were observed in
99.5% of the cases, and the positive tumour cell nuclei were
usually evenly distributed over the entire tumour area (Figure 1C).
PCNAtot was related neither to tumour thickness nor any other
clinicopathological variable (data not shown).
Univariate survival analysis
During the follow-up (mean 6.4 years), 106 patients (29%) had a
recurrence, 66 patients (18%) died of melanoma and 46 patients
(13%) died of other causes. The crude 5-year survival rate of the
patients was 78%. The 5-year overall survival (OS) rate of the
patients was 85%, and the 5-year recurrence-free survival (RFS) rate
was 76%. The corresponding survival rates among the subgroups
with valid p21, p53 and PCNA immunostainings were 83%, 85%
and 84% for OS and 73%, 75% and 74% for RFS respectively.
Significant clinicopathological factors predicting OS as well as RFS
in univariate analysis were gender, bleeding, tumour thickness,
Clark’s level of invasion and TNM category (Table 5).
We found no statistically significant relationship between the
expression level of p21 and OS or RFS of patients with melanoma,
even though there was a trend that the patients with highly p21
positive (> 20%) tumours had a better 5-year RFS (79%) than the
patients with p21-negative tumours (73%) (P = 0.076) (Table 5).
Further on, p21 expression was not associated with OS or RFS
within any tumour thickness subgroup. The high (> 10) p53 staining
index was a significant predictor of poor OS (P = 0.0086) and poor
RFS (P = 0.0112) in all patients (Table 5), as well as in patients with
tumour thickness > 1.5 mm (P = 0.001 for OS and P = 0.019 for
RFS) (other data not shown). We also tested the prognostic signifi-
cance of cytoplasmic p53 staining, but it had no impact on survival
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Table 4 Associations between p21 expression, p53 index and proliferation in stage I cutaneous malignant melanoma
p21 < 1% p21 1–10% p21 10–21% p21 > 20% c2 P-value
n (%) n (%) n (%) n (%)
p53 index
0 (0) 23 (54) 33 (35) 12 (21) 12 (20)
1 (≤1) 4 (9) 21 (22) 11 (19) 17 (28)
2 (1–10) 3 (7) 32 (34) 22 (39) 19 (32) 5.826 0.016
3 (>10) 13 (30) 9 (9) 12 (21) 12 (20)
Total 43 (100) 95 (100) 57 (100) 60 (100)
PCNAtot
≤35% 21 (78) 45 (65) 17 (45) 14 (30) 21.68 <0.00005
>35% 6 (22) 24 (35) 21 (55) 33 (70)
Total 27 (100) 69 (100) 38 (100) 47 (100)
p53 index 0 p53 index ≤1 p53 index 1–10 p53 index > 10 c2 P-value
n (%) n (%) n (%) n (%)
PCNAtot
≤35% 47 (65) 18 (46) 25 (44) 9 (35) 9.225 0.002
>35% 25 (35) 21 (54) 32 (56) 17 (65)
Total 72 (100) 39 (100) 57 (100) 26 (100)
PCNAtot, PCNA expression in ten consecutive high power fields; p53 index, (% of p53-positive tumour cells) ´ (staining intensity of p53).(data not shown). The patients with actively proliferating tumours
assessed by high (> 35%) PCNAtot expression had a worse 5-year
RFS compared with the patients with reduced (≤ 35%) levels, but
the difference between the survival curves was not signicant (P =
0.098) (Table 5). However, high PCNAtot expression predicted poor
RFS in patients with tumour thickness > 1.5 mm (P = 0.027) (other
data not shown). In OS, there was no statistical difference between
the survival curves in tumours of different PCNAtot categories (P =
0.55) (Table 5). To determine whether the actively proliferating
tumours might have different survival according to their p21 posi-
tivity, we separated the tumours by their p21 expression level and
proliferation status. Indeed, the combination of reduced p21 and
increased PCNA expression was a marker for poor RFS. However,
the difference was only of limited significance (P = 0.0636) (other
data not shown).
Multivariate survival analysis
There were 164 patients with a complete set of data available for a
multivariate Cox’s analysis. This included the significant clinico-
pathological variables of the univariate analysis (gender, bleeding,
tumour thickness, Clark’s level of invasion) completed by the
immunohistochemically determined variables (p21 expression,
p53 staining index and PCNAtot). The pT category (consisting of
Clark’s level of invasion and tumour thickness) was excluded from
the final model. Only tumour thickness (P = 0.0042) and bleeding
(P = 0.0087) predicted poor RFS as well as poor OS (P = 0.0147
for tumour thickness and P = 0.0033 for bleeding) in Cox’s
analysis (other data not shown). In the subset Cox’s analyses
according to tumour thickness, high p53 index (overall P = 0.038)
and bleeding (overall P = 0.042) were independently associated
with poor OS in patients with > 1.5-mm-thick tumours (n = 96).
No other combination proved to be of independent prognostic
value in OS or RFS analyses (other data not shown).
DISCUSSION
In the previous studies with clinical material, p21 expression has
correlated with tumour proliferation and differentiation either in a
p53-dependent (Doglioni et al, 1996; Harada et al, 1997; Wakasugi
et al, 1997) or in a p53-independent pathway (DiGiuseppe et al,
1995; Tron et al, 1996; Yasui et al, 1996; Nadal et al, 1997). So far,
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Table 5 Clinical, histological and immunohistochemical factors related to survival in stage I cutaneous malignant melanoma
Category (variable) No. of Recurrence-free 5 P-value* Surviving at 5 P-value*
patients years (RFS) (%) years (%)
Gender 0.0113 0.0056
Male 178 75 79
Female 191 89 89
Bleeding <0.00005 0.0002
Yes 98 74 77
No 152 90 92
Data not available 119 79 83
Clark’s level <0.00005 <0.00005
I2 1 9 4 9 4
II 68 98 98
III 106 90 92
IV 145 71 76
V2 9 6 5 6 5
Tumour thickness <0.00005 <0.00005
≤0.75 mm 82 97 97
0.76–1.50 mm 88 90 93
1.51–4.0 mm 120 74 78
>4.0 mm 50 57 63
TNM category
pT1 or T2, N0, M0 174 95 <0.00005 96 <0.00005
pT3, N0, M0 139 74 78
pT4, N0, M0 56 60 65
p21 expression 0.28 0.78
<1% 44 73 91
1–10% 103 73 84
10–20% 58 74 85
>20% 62 79 0.0762 84
p53 index 0.0112 0.0086
09 1 8 6 9 4
≤15 9 7 9 8 8
1–10 83 71 82
>10 51 55 0.0015 68 0.0013
PCNAtot 0.098 0.55
≤35% 114 81 87
>35% 105 66 80
PCNAtot, PCNA expression in ten consecutive high power fields; p53 index, (% of p53-positive tumour cells) ´ (staining intensity of p53); *log-rank analysis.only one clinical study has compared p21 expression with p53 in
cutaneous malignant melanoma (Maelandsmo et al, 1996).
Consequently, the prognostic role of p21 expression in cutaneous
malignant melanoma has not yet been defined.
The majority (84%) of the tumours in our material showed at
least 1% of their nuclei to express p21 protein. This result is
comparable with the study by Maelandsmo et al (1996), in which
69% of the primary melanomas and 57% of the metastases were
p21 positive. We found that thick tumours and tumours with high
pT category express significantly lower levels of p21 protein. This
observation contradicts the result of Maelandsmo et al (1996) in
superficially spreading melanomas, but supports the hypothesis
that loss of p21 function may be associated with melanoma
progression and with metastatic phenotype (Jiang et al, 1995;
Maelandsmo et al, 1996). The trend of reduced p21 expression in
recurrent disease further suggests that p21 may have a role in
melanoma growth suppression. Additional support for this comes
from the univariate survival analysis, in which tumours with high
(> 20%) levels of p21 expression had a little better 5-year RFS
(79%) than the p21-negative tumours (73%). However, this differ-
ence was not significant either in univariate or in multivariate
survival analysis, and this compares well with the results of
Maelandsmo et al (1996).
In line with the observations in breast cancer (Diab et al, 1997),
we found a significant association between the p21 and p53 expres-
sion levels (Tables 3 and 4). This suggests a p53-independent induc-
tion of p21 consistent with the findings in cutaneous melanoma cell
lines (Jiang et al, 1995; Vidal et al, 1995) or in cutaneous melanoma
in vivo (Maelandsmo et al, 1996). Unfortunately, the method used in
the present study didn’t allow us to exclude other possibilities for
our observation, such as stabilization of wt-p53 (Wynford-Thomas,
1992; Hall and Lane, 1994), exclusion of the protein into cytoplasm
(Moll et al, 1992) or p21 activation by p53 despite underlying p53
mutation (Ory et al, 1994; Harada et al, 1997).
Comparative studies have shown that immunohistochemical
detection of p53 is a good approximation of its real mutation (and
subsequent dysfunction) rate (Melhem et al, 1995; Nishio et al,
1996). Based on this, the observation of inverse correlation between
p21 and p53 immunopositivities would suggest a p53-dependent
mechanism of p21 activation. Indeed, we found several patients
with an inverse correlation between p21 and p53 expression (Table
4). In addition, there was a subgroup of patients with concomitant
lack of p53 and p21 expression (Table 4). It is possible that in some
of those tumours D07 antibody did not recognize all mutated forms
of p53 protein (Borresen et al, 1991). Moreover, other mechanisms
than mutation may cause p53 dysfunction, including complexing
with viral oncoproteins or with mdm-2 protein (Gelsleichter et al,
1995). Thus, the relationship between p21 expression and p53 is
complex and seems to be tumour-type specific.
Highly variable results of p53 immunoreactivity in primary
cutaneous melanoma (Weiss et al, 1995; Talve et al, 1996) have
been explained by differences in staining protocols, antibodies,
tumour materials (Talve et al, 1996) or cut-off levels used for
scoring (Gelsleichter et al, 1995). In our study, p53 immunoposi-
tivity was observed in 68% of the samples, which is a clearly
higher p53 expression level compared with the studies in which
the same antibody without antigen retrieval was used (Lassam et
al, 1993; Ro et al, 1993). In contrast, the fraction of immunoposi-
tivity in our material was very low, only about 20% of the tumours
showing p53 signal in more than 5% of the tumour cell nuclei.
This compares well with reports in which D07 antibody has been
used in human cutaneous malignant melanoma (Sparrow et al,
1995; Talve et al, 1996). A high p53 staining index was signifi-
cantly associated with poor RFS and OS in the univariate analyses,
but lost its significance in the multivariate analysis of all patients.
However, within the subgroup of patients with thick (>1.5 mm)
tumours, already known to have an impaired survival, p53 index
independently separated those patients into different prognostic
groups. Most studies to date have shown either no correlation
(Sparrow et al, 1995; Weiss et al, 1995; Talve et al, 1996) or, like
our study, an inverse (Yamamoto et al, 1995; Vogt et al, 1997)
correlation between the p53 expression and outcome of human
cutaneous malignant melanoma.
The high proliferation (PCNAtot) rate was related to the
increased p21 expression, which parallels the results in cutaneous
melanoma (Trotter et al, 1997) and in cutaneous squamous cell
carcinoma (Tron et al, 1996), but is in contrast to findings in other
neoplasms (Nadal et al, 1997) or in normal tissues (El-Deiry et al,
1995; Doglioni et al, 1996). The possible explanations of our
result may be either an abnormal function of p21 (Trotter et al,
1997) or that part of the tumour cells may have become refractory
to inhibitory signals from p21 (Yasui et al, 1996). It is also
possible that the tumour cells may up-regulate PCNA expression
as a response to elevated p21 expression levels to stay in the prolif-
erative compartment (Waga et al, 1994). In contrast, the elevated
p21 expression level may also be the result of a feedback mecha-
nism designed to halt proliferation (Jung et al, 1995).
The cell cycle regulatory effect of p21 interaction with PCNA
seems to be mediated only by large excess of p21 (Flores-Rozas et
al, 1994; Podust et al, 1995). With respect to this, we further subdi-
vided both PCNAtot categories into four groups according to their
p21 expression level. In the actively proliferating tumours
(PCNAtot >35%), high p21 positivity approached limited statis-
tical significance as a marker of favourable univariate RFS (P =
0.0636). Our finding may, thus, support the observation of tumour
growth inhibitory function of p21 in a p21–PCNA interaction
manner (Flores-Rozas et al, 1994; Waga et al, 1994; Podust et al,
1995).
There are only few reports on p53 expression with respect to
PCNA expression or other proliferation markers (Gelsleichter et
al, 1995; Naresh et al, 1997). Gelsleichter et al (1995) found a
positive correlation between p53 overexpression and MIB-1
expression in primary melanoma, whereas no association was
found between p53 and PCNA expression levels. We found a posi-
tive correlation between high PCNAtot positivity and increased
p53 index as did Naresh et al (1997) in Hodgkin’s disease. This
interesting result is in accordance with a suggestion that wt-p53
down-regulates PCNA expression, whereas the mutant form up-
regulates PCNA by activating its promoter (Deb et al, 1992). The
progression of a malignant tumour may also result in increasing
numbers of cells with abnormalities in DNA synthesis and subse-
quently in high levels of p53 and p21. To overcome their
inhibitory effects on the cell cycle, the PCNA levels may be kept
higher by independent mechanisms (Naresh et al, 1997).
In conclusion, our results suggest that there are both p53-
independent and p53-dependent pathways of p21 induction in
cutaneous malignant melanoma. Immunohistochemically detected
positive p53 (mutation or protein stabilization) was the only
prognostically significant protein associated with poor disease
outcome, especially within thick tumours. Even though elevated
p21 expression may indicate favourable prognosis in clinical stage
I cutaneous melanoma, it is probable that the growth inhibitory
900 JM Karjalainen et al
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yet unknown, mechanisms. Such mechanisms could include inter-
action with inhibitory proteins (Gadd45) (Chen et al, 1995), cyclin
D, E2F (Hiyama et al, 1997), or with other molecules (AP-2)
(Zeng et al, 1997).
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